RecruitingNCT03053141

RHythmia mAPping and Signal acquisitiOn for Data analYsis (RHAPSODY)

Sponsor

Boston Scientific Corporation

Enrollment

100 participants

Start Date

May 1, 2016

Study Type

OBSERVATIONAL

Conditions

Cardiac Arrythmias

Summary

The objective of the RHAPSODY study is to evaluate the performance of new software features in subjects undergoing standard of care catheter-based endocardial mapping for atrial or ventricular tachyarrhythmias using a commercial Rhythmia Mapping System. Results from this study will be used to guide development and refinement of new software features that may be implemented in future commercial software releases.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a medical device called Rhythmia Mapping System for people with cardiac arrythmias. The study is currently recruiting participants at 8 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICERhythmia Mapping System

The Rhythmia Mapping System is a 3D electro-anatomical mapping system.

Locations(8)

University of Alabama at Birmingham

Birmingham, Alabama, United States

St. Lukes Idaho Cardiology Associates

Boise, Idaho, United States

Lahey Clinic, Inc.

Burlington, Massachusetts, United States

Cardiovascular Specialists of New England Research Foundation

Londonderry, New Hampshire, United States

Catholic Medical Center

Manchester, New Hampshire, United States

Valley Hospital

Ridgewood, New Jersey, United States

Fondazione Centro San Raffaele

Milan, MI, Italy

Centre Hospitalier Princesse Grace

Monaco, Monaco

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03053141

Related Trials